Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on NeuroPace (NASDAQ:NPCE) and maintained a price target of $18.
August 14, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on NeuroPace (NASDAQ:NPCE) and maintained a price target of $18.
The reiteration of an Overweight rating and the maintenance of a price target at $18 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100